nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.187	0.282	CbGbCtD
Tasosartan—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.126	0.19	CbGbCtD
Tasosartan—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.12	0.182	CbGbCtD
Tasosartan—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.107	0.162	CbGbCtD
Tasosartan—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.063	0.0949	CbGbCtD
Tasosartan—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0595	0.0897	CbGbCtD
Tasosartan—AGTR2—respiratory system—chronic obstructive pulmonary disease	0.036	0.456	CbGeAlD
Tasosartan—AGTR2—ACE Inhibitor Pathway—ACE—chronic obstructive pulmonary disease	0.0272	0.11	CbGpPWpGaD
Tasosartan—AGTR2—lung—chronic obstructive pulmonary disease	0.0191	0.242	CbGeAlD
Tasosartan—AGTR2—ACE Inhibitor Pathway—NOS3—chronic obstructive pulmonary disease	0.0127	0.0512	CbGpPWpGaD
Tasosartan—AGTR2—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.0114	0.0463	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—ACE—chronic obstructive pulmonary disease	0.00886	0.0359	CbGpPWpGaD
Tasosartan—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00875	0.0354	CbGpPWpGaD
Tasosartan—AGTR2—ACE Inhibitor Pathway—TGFB1—chronic obstructive pulmonary disease	0.00837	0.0339	CbGpPWpGaD
Tasosartan—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00773	0.0313	CbGpPWpGaD
Tasosartan—AGTR1—connective tissue—chronic obstructive pulmonary disease	0.0071	0.0899	CbGeAlD
Tasosartan—AGTR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00649	0.0822	CbGeAlD
Tasosartan—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00632	0.0256	CbGpPWpGaD
Tasosartan—AGTR1—trachea—chronic obstructive pulmonary disease	0.00596	0.0755	CbGeAlD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.00537	0.0218	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.00453	0.0184	CbGpPWpGaD
Tasosartan—AGTR1—lung—chronic obstructive pulmonary disease	0.00428	0.0542	CbGeAlD
Tasosartan—AGTR1—Arf6 signaling events—ADRB2—chronic obstructive pulmonary disease	0.00425	0.0172	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.00421	0.017	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—NOS3—chronic obstructive pulmonary disease	0.00413	0.0167	CbGpPWpGaD
Tasosartan—AGTR1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00372	0.0151	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.0036	0.0146	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 trafficking events—ADRB2—chronic obstructive pulmonary disease	0.00336	0.0136	CbGpPWpGaD
Tasosartan—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00321	0.013	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.00313	0.0127	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.00301	0.0122	CbGpPWpGaD
Tasosartan—Irbesartan—CYP1A2—chronic obstructive pulmonary disease	0.00294	0.271	CrCbGaD
Tasosartan—AGTR1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.00288	0.0117	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.00275	0.0111	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—TGFB1—chronic obstructive pulmonary disease	0.00273	0.011	CbGpPWpGaD
Tasosartan—Losartan—ACE—chronic obstructive pulmonary disease	0.00267	0.246	CrCbGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.00264	0.0107	CbGpPWpGaD
Tasosartan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.00246	0.00996	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.00226	0.00915	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.00225	0.0091	CbGpPWpGaD
Tasosartan—Valsartan—ALB—chronic obstructive pulmonary disease	0.00224	0.207	CrCbGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.00206	0.00835	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.00202	0.00818	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.00196	0.00793	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.00192	0.00779	CbGpPWpGaD
Tasosartan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00191	0.00772	CbGpPWpGaD
Tasosartan—Losartan—CYP1A2—chronic obstructive pulmonary disease	0.0019	0.175	CrCbGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.00177	0.00716	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.00175	0.00709	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.00175	0.00707	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—chronic obstructive pulmonary disease	0.00174	0.00704	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.00172	0.00697	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.00166	0.00671	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.00163	0.00659	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.00155	0.00628	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.00154	0.00623	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00151	0.00611	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	0.0015	0.00608	CbGpPWpGaD
Tasosartan—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.00144	0.00585	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.00141	0.0057	CbGpPWpGaD
Tasosartan—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00139	0.00561	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.00137	0.00556	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.00137	0.00555	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.00136	0.00551	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.00135	0.00545	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00133	0.0054	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.0012	0.00487	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.00117	0.00475	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00116	0.00468	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.0011	0.00444	CbGpPWpGaD
Tasosartan—Losartan—ALB—chronic obstructive pulmonary disease	0.0011	0.101	CrCbGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.00109	0.00442	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—chronic obstructive pulmonary disease	0.00107	0.00435	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.00107	0.00433	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.00103	0.00418	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.00103	0.00416	CbGpPWpGaD
Tasosartan—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00101	0.00408	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000994	0.00402	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000982	0.00397	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000973	0.00394	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000969	0.00392	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000907	0.00367	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000894	0.00362	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000889	0.0036	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000884	0.00358	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.00087	0.00352	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.00087	0.00352	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.00087	0.00352	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.00086	0.00348	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000832	0.00337	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000832	0.00337	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.000798	0.00323	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.00079	0.0032	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000778	0.00315	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000761	0.00308	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.000745	0.00302	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000737	0.00298	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000733	0.00297	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000712	0.00288	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000691	0.0028	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000672	0.00272	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000658	0.00267	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000627	0.00254	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000608	0.00246	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000589	0.00238	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000576	0.00233	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000576	0.00233	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000569	0.00231	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000568	0.0023	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000566	0.00229	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000561	0.00227	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000531	0.00215	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000522	0.00211	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000517	0.00209	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000505	0.00205	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000501	0.00203	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.00047	0.0019	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000467	0.00189	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000467	0.00189	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000459	0.00186	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000444	0.0018	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000439	0.00178	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000427	0.00173	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000424	0.00172	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000418	0.00169	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000413	0.00167	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000408	0.00165	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000379	0.00154	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000356	0.00144	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000351	0.00142	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000339	0.00137	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000336	0.00136	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000317	0.00128	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	0.000312	0.00126	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000298	0.00121	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	0.000298	0.00121	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000295	0.00119	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000288	0.00117	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	0.000284	0.00115	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000283	0.00115	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000271	0.0011	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000271	0.0011	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.00027	0.00109	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000257	0.00104	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	0.000252	0.00102	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000248	0.001	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000248	0.001	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000244	0.00099	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	0.00024	0.00097	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	0.000228	0.000923	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000225	0.000911	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000207	0.000837	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	0.000205	0.000829	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000204	0.000825	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000198	0.000803	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.00019	0.000769	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	0.000188	0.000761	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000187	0.000759	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000184	0.000746	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	0.000184	0.000746	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.00018	0.000729	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000178	0.000719	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.00017	0.000689	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	0.000155	0.000626	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000153	0.00062	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000152	0.000615	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	0.000145	0.000587	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	0.000142	0.000573	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000139	0.000563	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000138	0.000559	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000133	0.000538	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000124	0.0005	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	0.000102	0.000411	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.7e-05	0.000393	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.6e-05	0.000389	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	9.34e-05	0.000378	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.26e-05	0.000375	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.68e-05	0.000351	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.22e-05	0.000333	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.81e-05	0.000316	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.43e-05	0.000301	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.67e-05	0.00027	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.12e-05	0.000248	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.01e-05	0.000243	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.1e-05	0.000206	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.04e-05	0.000204	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.04e-05	0.000204	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.62e-05	0.000187	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.6e-05	0.000186	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.24e-05	0.000172	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.54e-05	0.000143	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.49e-05	0.000141	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.25e-05	0.000132	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.08e-05	0.000125	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.09e-05	8.48e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2e-05	8.11e-05	CbGpPWpGaD
